Another Step Towards Myeloma Market Dominance For Amgen's Kyprolis
This article was originally published in Scrip
Executive Summary
Amgen Inc.'s Kyprolis (carfilzomib) has been given the green light in Europe for the treatment of relapsed multiple myeloma, after being pushed through reviews under the European Medicines Agency's accelerated assessment program.
You may also be interested in...
Amgen's Kyprolis Miss In First-Line Myeloma Surprising, But Clinically Irrelevant
Because CLARION was designed to test Kyprolis head-to-head against fellow proteasome inhibitor Velcade, the failure could hurt the drug's standing in its class. But the trial design used a regimen largely phased out of clinical practice and Amgen has other chances to prove superiority.
Deals Shaping The Medical Industry, March 2021
Derived from Biomedtracker, the Deal-Making column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in March 2021. Data provided by Biomedtracker.
Deals Shaping The Medical Industry, February 2021
Derived from Biomedtracker, the Deal-Making column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in February 2021. Data provided by Biomedtracker.